Cellular and molecular regulation of the programmed death-1/programmed death ligand system and its role in multiple sclerosis and other autoimmune diseases

Simple item page
dc.contributor.authorIbanez-Vega, Jorge
dc.contributor.authorVilchez, Constanza
dc.contributor.authorJimenez, Karin
dc.contributor.authorGuevara, Carlos
dc.contributor.authorBurgos, Paula, I
dc.contributor.authorNaves, Rodrigo
dc.date.accessioned2025-01-20T22:10:38Z
dc.date.available2025-01-20T22:10:38Z
dc.date.issued2021
dc.description.abstractProgrammed Cell Death 1 (PD-1) receptor and its ligands (PD-Ls) are essential to maintain peripheral immune tolerance and to avoid tissue damage. Consequently, altered gene or protein expression of this system of coinhibitory molecules has been involved in the development of cancer and autoimmunity. Substantial progress has been achieved in the study of the PD-1/PD-Ls system in terms of regulatory mechanisms and therapy. However, the role of the PD-1/PD-Ls pathway in neuroinflammation has been less explored despite being a potential target of treatment for neurodegenerative diseases. Multiple Sclerosis (MS) is the most prevalent, chronic, inflammatory, and autoimmune disease of the central nervous system that leads to demyelination and axonal damage in young adults. Recent studies have highlighted the key role of the PD-1/PD-Ls pathway in inducing a neuroprotective response and restraining T cell activation and neurodegeneration in MS. In this review, we outline the molecular and cellular mechanisms regulating gene expression, protein synthesis and traffic of PD-1/PD-Ls as well as relevant processes that control PD-1/PD-Ls engagement in the immunological synapse between antigen-presenting cells and T cells. Also, we highlight the most recent findings regarding the role of the PD-1/PD-Ls pathway in MS and its murine model, experimental autoimmune encephalomyelitis (EAE), including the contribution of PD-1 expressing follicular helper T (TFH) cells in the pathogenesis of these diseases. In addition, we compare and contrast results found in MS and EAE with evidence reported in other autoimmune diseases and their experimental models, and review PD-1/PD-Ls-targeting therapeutic approaches.
dc.description.funderFONDECYT Regular
dc.fuente.origenWOS
dc.identifier.doi10.1016/j.jaut.2021.102702
dc.identifier.eissn1095-9157
dc.identifier.issn0896-8411
dc.identifier.urihttps://doi.org/10.1016/j.jaut.2021.102702
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/94381
dc.identifier.wosidWOS:000685545200002
dc.language.isoen
dc.revistaJournal of autoimmunity
dc.rightsacceso restringido
dc.subjectProgrammed death-1 (PD-1)
dc.subjectProgrammed death ligand-1 (PD-L1)
dc.subjectProgrammed death ligand-2 (PD-L2)
dc.subjectNeuroinflammation
dc.subjectMultiple sclerosis (MS)
dc.subjectAutoimmune diseases
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleCellular and molecular regulation of the programmed death-1/programmed death ligand system and its role in multiple sclerosis and other autoimmune diseases
dc.typeartículo
dc.volumen123
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas